Proscia Inc., a Center City-based digital pathology services company, has received a crucial Food and Drug Administration approval, writes John George for the Philadelphia Business Journal. 

The 510(k) clearance the FDA granted Proscia is required for a manufacturer to market a medical device.

With this approval, the company will now be able to market its Concentriq AP-Dx product to a wider audience. 

Concentriq is a software platform used to improve and streamline the interpreting, storing, and sharing of digital images of biopsies. 

“[This] is a big moment for us, both in terms of expanding our customer base and seeing through our mission to perfect cancer diagnosis,” Proscia CEO David West said about the 510(k) clearance.

Proscia also has a separate digital pathology product line that life sciences organizations use for drug research and development.

Overall, the company’s platform is used by more than 10,000 pathologists and researchers at reference labs, academic medical centers, clinical research organizations, biotechnology firms, and 14 of the top 20 global pharmaceutical companies. 

“The timing [of the FDA clearance] couldn’t be better,” West said. “Laboratories continue to face mounting pressures [including recruitment and staff utilization], and digital pathology is the answer.”

Read more about Proscia and its plans to market its technology to a wider audience at the Philadelphia Business Journal. 

_____